Kindred Biosciences, Inc. (KIN) Q4 2019 Earnings Conference Call March 16, 2020 4:30 PM ET
Company Participants
Richard Chin - Founder and CEO
Wendy Wee - CFO
Denise Bevers - Founder, President and COO
Conference Call Participants
Brandon Folkes - Cantor Fitzgerald
Jon Block - Stifel
Balaji Prasad - Barclays
David Westenberg - Guggenheim Securities
Swayampakula Ramakanth - HC Wainwright
Ben Haynor - Alliance Global
Brooks O'Neil - Lake Street Capital
Nathan Weinstein - Aegis Capital
Operator
Welcome to the Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast for Kindred Biosciences. At this time, all participants have been placed on a listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. [Operator Instructions] Please be advised that today's conference is being recorded [Operator Instructions].
Please note that the remarks today will include forward-looking statements, and that actual results could differ materially from those projected or implied in our forward-looking statements. For a description of important factors that could cause actual results to differ, we refer you to the forward-looking statements in today's press release and the note on forward-looking statements in the company's SEC filings.
It is now my pleasure to turn the call over to KindredBio's, CEO, Richard Chin. Dr. Chin, please proceed.
Richard Chin
Thank you, operator. Good afternoon and welcome to our year-end 2019 financial results call. Joining me today from the management team of KindredBio are Denise Bevers, our President and COO; Wendy Wee, our CFO; and Katja Buhrer, our VP of Corporate Development and Investor Relations.
2019 was an extremely successful year with two approvals, multiple positive pilot studies, the commencement of two pivotal studies, as well as the development of our Half-Life Extension technology. We're very proud of the progress we made last year.
- Read more current ELAN analysis and news
- View all earnings call transcripts